Key facts
- Integra Therapeutics’s last known valuation is $9.3M (Jan 2023).
- It has raised $19.1M; the latest was Early Stage VC ($12.5M) in Sep 2025.
- Notable investors include European Innovation Council, INNVIERTE SICC, CDTI Innvierte, Takeda Ventures, AdBio partners — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for Integra Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Integra Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Integra Therapeutics
Developer of gene writing tools designed to unlock the full potential of gene therapy to meet patients' needs. The company combines the precision of CRISPR systems with the gene transfer efficiency of viral integrases and transposases and addresses the current limitations of gene editing, enabling scientists to introduce DNA into a genome with sequence-specific DNA binding proteins for developing gene therapies.
- Sector
- Healthcare
- HQ
- Barcelona, Spain
- Founded
- 2020
- Employees
- 20
- Website
- integra-tx.com/
- Ownership
- Privately Held (backing)
Integra Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Integra Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Integra Therapeutics in its N-PORT filings yet. We sweep new filings monthly.